Thyrocare Technologies · NSE: THYROCARE · BSE: 539871

Q3 FY20 results · Oct–Dec 2019

Thyrocare Technologies reported revenue from operations of ₹105.79 crore (up 9.9% from Q3 FY19) and net profit of ₹27.51 crore (up 36.5% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
ItemQ3 FY20Q3 FY19YoYQ2 FY20QoQ
Revenue from operations105.7996.29+9.9%116.24−9.0%
Other income0.853.34−74.6%2.46−65.4%
Total income106.6499.63+7.0%118.70−10.2%
Profit before share of associates & JVs and tax36.4231.82+14.5%45.78−20.4%
Share of profit/(loss) of associates & JVs0.080.170.27
Net profit for the period27.5120.15+36.5%35.05−21.5%
EPS, basic (₹)5.213.81+36.7%6.73−22.6%
Net margin (%)26.020.930.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ3 FY20Q3 FY19YoYQ2 FY20QoQ
Revenue from operations97.9988.12+11.2%107.89−9.2%
Other income1.304.38−70.3%3.36−61.3%
Total income99.2992.50+7.3%111.25−10.8%
Profit before tax38.9034.42+13.0%48.43−19.7%
Net profit for the period29.9122.44+33.3%37.43−20.1%
EPS, basic (₹)5.664.25+33.2%7.22−21.6%
Net margin (%)30.525.534.7
Consolidated
Filed with BSE
03 Feb 2020, 14:57 IST
Board meeting
01 Feb 2020
Period
01 Oct 2019 to 31 Dec 2019
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
03 Feb 2020, 14:57 IST
Board meeting
01 Feb 2020
Period
01 Oct 2019 to 31 Dec 2019
Review status
Unaudited
Source
XBRL filing on BSE